RTP-based SCYNEXIS, Inc. (www.scynexis.com), a chemistry-focused drug discovery and development company, has entered into a multi-year research agreement with Merck & Co., Inc. to discover and develop novel oncology compounds. Through the use of its proprietary technologies, SCYNEXIS will produce highly-targeted compound libraries and utilize rapid lead optimization techniques to develop new drug candidates for clinical evaluation.
SCYNEXIS focuses on delivering drug pipeline solutions to its pharmaceutical partners. SCYNEXIS' research teams integrate computational chemistry, medicinal chemistry, bioanalysis and process chemistry.
SCYNEXIS is a CED member.